Isotechnika's Independent Data Monitoring Committee Conducts Review of Phase 2b Kidney Transplant Trial

Edmonton (ots/PRNewswire) -

- Company Set to Host Evening Symposium at ATC

Isotechnika Inc. announced today that an independent data
monitoring committee (DMC) has met and reviewed the interim data
from the Phase 2b kidney transplant (PROMISE) trial. The review
included 3 month data from approximately 1/3 of the anticipated 332
patients to be enrolled. The DMC has recommended that the trial
continue according to the original study design. There were no
concerns in this review with regards to the safety or efficacy of
ISA247 in this patient population.

"The DMC was formed as a special safeguard to ensure the best
interests of the patients participating in this trial," commented
Dr. Yatscoff, Isotechnika's President & CEO. "Their independent
review of the three month data is consistent with our internal
analysis which suggests that ISA247 is safe and efficacious in this
patient population."

Following the independent review by the DMC, Isotechnika is set to
host an evening symposium at the American Transplant Congress this
May. Further details regarding the symposium will be forthcoming.

North American Phase 2b Kidney Transplant Study Design

Forty-one centers across North America have been contracted to
perform the trial, including thirty-seven centers in the United
States and four centers in Canada. The primary endpoint of the trial
is defined as non- inferiority in biopsy proven acute rejection
(BPAR) episodes in patients receiving ISA247 for six months as
compared to the tacrolimus control which is currently the North
American leading transplant drug in this class. Additionally, kidney
function and other laboratory parameters will be monitored for the
duration of the trial. The overall goal of the trial is to find the
most appropriate dose that will result in efficacy (lack of acute
rejection) with minimal side effects that are typically seen with
other calcineurin inhibitors such as cyclosporine and tacrolimus.

A total of 332 de novo (newly transplanted) kidney transplant
patients will be enrolled in this trial. Patients will be placed
into one of four separate treatment groups; three different dose
groups of ISA247 (0.4 mg/kg, 0.6 mg/kg, and 0.8 mg/kg twice daily
compared with the fourth group, a tacrolimus (0.05 mg/kg twice
daily) control arm. Patients in all four treatment groups will have
their doses adjusted in order to achieve pre- defined blood levels of
either ISA247 or tacrolimus. All patients will receive oral
treatment of drug (ISA247 or tacrolimus) over a six month period
along with other standard immunosuppressive therapies used following
transplantation.

About Isotechnika

Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world- class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies.

Isotechnika's lead compound, ISA247 has successfully completed a
Phase 3 Canadian trial for the treatment of moderate to severe
psoriasis. ISA247 is currently being investigated in a combined
Phase 3 European/Canadian psoriasis trial and a Phase 2b North
American trial for the prevention of kidney graft rejection. Our
partner, Lux Biosciences has received permission from the Food and
Drug Administration to investigate ISA247 in three separate pivotal
Phase2/Phase 3 trials for the treatment of non-infectious uveitis and
as a maintenance therapy in uveitis. The Company also successfully
completed Phase 1 clinical trials of an additional immunosuppressive
compound in its drug pipeline, TAFA93. Isotechnika Inc. is a
publicly traded company on the Toronto Stock Exchange under the
symbol "ISA". More information on Isotechnika can be found at
www.isotechnika.com.

Partnerships with Isotechnika Inc.

Isotechnika Inc. signed a collaboration agreement with Hoffman La
Roche on April 9, 2002, which licensed the worldwide rights to
develop and commercialize ISA247 for all transplant indications.

On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the
use of ISA247 and TAFA93 specifically with drug eluting devices for
the non-systemic treatment of vascular, cardiovascular, target
vessel and tissue disorders.

Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April 25, 2006, granting Isotechnika the option to obtain an
exclusive license to develop and commercialize conjugates consisting
of Cellgate's patented transporter technology for the topical
delivery of ISA247 in patients suffering from mild to moderate
psoriasis.

On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead
drug, ISA247 for the treatment and prophylaxis of all ophthalmic
diseases.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Dr. Randall Yatscoff, President & COO,
Isotechnika Inc., Phone: +1-(780)-487-1600 Ext. 246, Fax:
+1-(780)-484-4105, Email: ryatscoff@isotechnika.com; Stephanie
Gillis-Paulgaard, Director, Corporate Communications, Isotechnika
Inc., Phone: +1-(780)-487-1600 Ext. 243, Fax: +1-(780)-484-4105,
E-mail:sgillis-paulgaard@isotechnika.com (ISA.)